since zyprexa trial ongoing alaska i thought i return wonderful world zyprexa i encourage readers follow zyprexa coverage furious seasons pharmalot pharmagossip today i discuss link key opinion leaders marketing zyprexa preface coveted golden goblet nomination could handed several individuals based involvement zyprexa marketing march zyprexa received fda approval treatment manic episodes one document laid multipronged marketing maneuvers lilly utilized move zyprexa shortly approval details document well covered terrific piece investigative journalism furious seasons post provide coverage link zyprexa key opinion leaders helped popularize drug across nation approved bipolar disorder lilly utilized several tactics market zyprexa bipolar disorder including satellite conference beamed physicians treatment team members facilities faculty providing educational service included many big names academic psychiatry including paul keck jan fawcett hagop akiskal alan schatzberg alan schatzberg say yes alan schatzberg set become president american psychiatric association less pleased election apa president considering background physician marketer key opinion leader large conflicts interest alan schatzberg involved marketing passing continuing medical education lilly also bankrolled dinner meetings anticipated draw physicians per sitting dr schatzberg also listed speaker dinners one mental health service provider impressed enough receiving excellent medical education find cv document outlining zypexa big marketing launch paul keck name appears following contexts satellite symposium provider trainer local speakers i believe means would train local physicians various markets discuss zyprexa colleagues faculty bipolar weekend symposia faculty audio conferences faculty satellite cme workshop faculty dissemination bipolar information customers faculty closed symposium resulting cme newsletter cme audiotape mailed individuals author two journal supplement articles paul keck also member task force chartered american psychiatric association served revise organization guidelines provide favorable view atypical antipsychotics including zyprexa treatment bipolar disorder conflict interest eh keck said interview often keck said patients bipolar disorder require complex treatment regimens manage phases illness creating compliance challenge patients management challenge clinicians studies suggest physicians may able use olanzapine foundation simplify patients treatment regimens combination olanzapine fluoxetine could effective treatment choice likely keck performing educational functions lilly exchange lollipops likely receiving healthy dose cold hard cash yet article nothing written financial links lilly keck also appeared press releases saying nice things symbyax fluoxetine olanzapine combination fair keck also stumped pfizer geodon press releases oh also said nice things abilify press release i suppose one going true key opinion leader real mover shaker one prepared say nice things whatever new drug released since new drug naturally represents important treatment option keck like alan schatzberg charles nemeroff also currently listed member clinical advisory board neuroscience cme profit entity awash drug industry money dr daniel carlat previously written educational content produced organization biased i find easy believe hard find examples poorly done industry funded cme fact might interested reading cme activity nemeroff seems pulled data thin air sum usual fun games play zyprexa initially pushed bipolar disorder biggest names psychiatry left fingerprints marketing zyprexa one key opinion leaders recently presidential election american psychiatric association i suppose american psychiatrists generally either unaware conflicts interest care beautiful thing key opinion leader one name recognition huge among psychiatrists i bet schatzberg name better known bill clinton since schatzberg byline appears journal supplements cme frequently ca hurt running president national professional organization i interested see schatzberg handles questions conflicts interest drug industry influence profession expecting major efforts reform near future